Introduction
Surfacide Mexico, a leading company in UV-C light disinfection technology, has invited hospitals of the second and third levels in Mexico City and its metropolitan area to participate in a multi-center research study. The aim is to evaluate the clinical impact of advanced UV-C light disinfection to proactively and continuously reduce healthcare-associated infections (HAIs).
From Reaction to Prevention
The primary focus of the study is to validate “preventive disinfection,” transforming current reactive protocols—where deep cleaning is activated only after confirmed contamination or patient discharge—into a routine and automated system. Marco Antonio Guerrero, the biomedical director of Surfacide in Mexico, emphasizes that this approach will be applied in critical areas such as operating rooms and intensive care units, regardless of visible bacterial load.
By joining this initiative, participating hospitals will not only contribute to scientific evidence generation but also strengthen their capabilities for infection prevention, safeguarding patients and medical staff from multi-drug-resistant pathogens.
FDA-Approved Technology
The study will utilize the Helios UV-C system, recently approved by the U.S. Food and Drug Administration (FDA) as a Class II medical device. Surfacide highlights that this authorization positions the company as the first in its category to emit continuous and safe UV-C light, demonstrating effectiveness against multi-resistant pathogens in extensive tests.
This technology, according to the company, is a crucial tool for hospitals seeking innovation in infection prevention, offering measurable results backed by international standards.
Study Methodology and Benefits
The hospital protocol will last between six months and one year, allowing for seasonal variation control in infection rates. According to the plan, researchers will compare each hospital’s historical data with post-implementation results of the Helios UV-C system, measuring reductions in HAIs and other clinical indicators.
Among the highlighted incentives for participating hospitals:
- Permanent donation of equipment: At the study’s conclusion, institutions will receive Helios UV-C systems as fixed assets without acquisition cost, only covering importation and shipping expenses.
- Training and certification: Healthcare professionals, including epidemiologists, infectious disease specialists, and nurses, will receive official training and certification in technology handling.
- Academic recognition: Participation as co-authors in the publication of results, with opportunities to present them at national and international medical forums.
Guerrero pointed out that the benefit extends beyond improving hospital infrastructure, as it empowers medical institutions to lead infection prevention efforts, aligning with sustainable public health goals.
Strategic Allies and Call for Hospitals
The initiative has the support of key organizations in this field, including the Mexican Association for Sterilization Processing (AMEXPE), the Mexican Association for Nosocomial Infection Studies (AMEIN), the Mexican Federation of Surgical Nursing, and the Hospitals Without Infections (HsI) initiative, ensuring a collaborative and expert framework.
Hospitals interested in preventing infections and joining this transformative study can register until January 31, 2026, through surfacidemexico.com. The selection of the ten participants will be based on an assessment of their epidemiological surveillance capabilities, with subsequent notification.
Guerrero stated that this call represents a unique opportunity for public hospitals committed to innovation in hygiene, contributing to a safer and more efficient healthcare system in Mexico.
Key Questions and Answers
- What is the purpose of the study? The research aims to evaluate the clinical impact of advanced UV-C light disinfection to proactively and continuously reduce healthcare-associated infections (HAIs).
- Which hospitals are eligible to participate? Hospitals of the second and third levels in Mexico City and its metropolitan area are invited to join.
- What technology will be used in the study? The Helios UV-C system, recently approved by the U.S. FDA as a Class II medical device, will be employed.
- What benefits do participating hospitals receive? Hospitals will receive permanent donation of Helios UV-C systems, training and certification for healthcare professionals, academic recognition, and more.
- When and how can hospitals register? Hospitals can register until January 31, 2026, through surfacidemexico.com.
